SEI Investments’s Immunome IMNM Stock Holding History

SEI Investments’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$4.45M	Buy	206,892 +144,409	+231%	+$3.58M	﹤0.01%	1528
2026 Q2	$1.32M	Buy	62,483 +9,713	+18%	+$208K	﹤0.01%	2158
2026 Q1	$1.15M	Buy	52,770 +25,051	+90%	+$558K	﹤0.01%	2290
2025 Q4	$595K	Buy	+27,719	New	+$486K	﹤0.01%	2429
2024 Q4	–	Sell	-14,918	Closed	-$218K	–	2754
2024 Q3	$218K	Buy	14,918 +2,380	+19%	+$33.8K	﹤0.01%	2447
2024 Q2	$152K	Sell	12,538 -6,452	-34%	-$101K	﹤0.01%	2492
2024 Q1	$469K	Buy	+18,990	New	+$385K	﹤0.01%	2131

Other funds holding IMNM

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.04B AUM 32.17% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Alerus Financial Grand Forks, North Dakota $2.27B AUM 22.87% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

SEI Investments's IMNM Position: Q3 2026 in Review

SEI Investments increased its Immunome (IMNM) stake by 231% in Q3 2026, buying an estimated $3.58M and bringing the position to 206,892 shares worth $4.45M. The position accounts for ﹤0.01% of the portfolio, ranked #1528.

SEI Investments first reported a position in IMNM in Q1 2024 and has held it in 7 quarters since. 84 funds tracked by Wall St. Rank hold IMNM as of Q3 2026.

SEI Investments held 206,892 shares of Immunome worth $4.45M as of Q3 2026.
SEI Investments bought 144,409 Immunome shares in Q3 2026, an estimated $3.58M.
Immunome made up ﹤0.01% of SEI Investments's portfolio in Q3 2026, its #1528 holding.
SEI Investments first reported a position in Immunome in Q1 2024 and has held it in 7 quarters since.
84 funds tracked by Wall St. Rank held Immunome as of Q3 2026.

Based on SEI Investments's 13F filing for Q3 2026, filed 10 Nov 2026.